Metsera initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...
Metsera initiated as Early-Stage Biotech at Goldman Sachs
Goldman Sachs analyst Chris Shibutani initiated coverage of Metsera (MTSR) as an Early-Stage Biotech. Metsera is clinical-stage ...
Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently
We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...
BioSpace11d
Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
ETF Daily News14d
Metsera, Inc. Files Amended Certificate of Incorporation and Restated Bylaws
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Alongside the amended certificate, Metsera, Inc. also updated its bylaws.
BioPharma Dive18d
Vertex challenger Sionna prices $191M IPO
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
manilatimes19d
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...
FOX 40 WICZ TV19d
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...
Mena FN20d
Metsera Announces Closing Of Initial Public Offering And Full Exercise And Closing Of Underwriters’ Option To Purchase Additional Shares
(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company ...
Investing21d
Metsera shares leap on strong IPO performance
Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...